## Hematopathology, Molecular, and Flow Cytometry Requisition



4142 South Mingo Road, Tulsa, (918) 417-6400 Fax (	OK. 74146 (918) 416-0506			Pathology Laboratory Associate
PATIENT INFORMATION (Please Prov		n)		
LAST NAME (Please Print Legibly) FIRST	MIDDLE	PATIENT MRN.		SEX DATE OF BIRTH [ MM / DD / YYYY ]
				MD FD
ORDERING PROVIDER		DOCTOR PHONE NUMBER		CLIENT NAME/NUMBER
ORDERING PROVIDER SIGNATURE				
X:				
COLLECTION DATE:				
COLLECTION BATE.	Specimen	☐ Bone marrow and blood	☐ Body fluid: Type	Case No:
TIME: A.M.	Information	☐ Peripheral blood	☐ Tissue: Type	Prior Case No:
□ P.M.		in empiricial blood		BTHOLCASC NO.
				cytogenetic, flow cytometry, FISH and molecular tests n may be required to perform testing.
Clinical Findings or History ICI	D10 codes (must	have appropriate codes for tes	ting):	
Working diagnoses/concerns				
Evaluation requested			_	
Complete Bone marrow and peripheral blood evaluation (including flow				Flow Cytometry
cytometry, cytogenetics, FISH and molecular stud		, ,	-	Screening panel (blasts, lymphocytes,
Hemepath Consult (CBC and Pathologist report of findings)				myeloid cells (expand if needed)
HemePath Consult with Client Submitted CBC				T and B cell disorder/lymphoma panel
Tissue or fluid morphologic assessment: Type				(expand if needed)
☐ Microbiology Cultures -				Plasma cell neoplasm/myeloma
☐ Anaerobic ☐ Aerobic ☐ Fungus ☐ AFB				Acute leukemia panel
(Note: Molecular testing recommended for viral infection evaluation, not viral cultures)				PNH Panel
Myeloid Neoplasms/myeloprolid  NGS Panel, myeloid disorders  FISH: PML/RARA, t(15;17) for Leukemia  FISH: 11q23 (MLL/KMT2A) Refish: AML1/ETO, t(8,21)  FISH: CBFB, Inv(16), t(16;16)  FISH: BCR/ABL t(9;22)  FISH: Myeloid Disorder Panel  PCR: PML/RARA t(15;17), Qual  PCR: CEBPA Mutation  PCR: FLT3 Mutations (ITD)  PCR:RUNX1 Mutation  PCR: NPM1 (Exon 12) Mutation  PCR: IDH1/IDH2 Mutation  PCR: JAK2 V617F Mutation  MPN Molecular Panel includir (only performed if negative for FISH: CHIC2 deletion (FIP1L1-I (rearrangements will be deternallysis	carrangement (chromosomes ntitative  ang JAK2 exon 12 or JAK2 V617F) PDGFRA) 4q12 I	5, 7, 8, 20) 2, MPL, CALR PDGFRB and FLP1	FISH: 11q23 (MLL/KMT2 FISH: t(12:21) ETV/RUN: PCR: BCR/ABL t(9;22), q Lymphoma, LPDs, and Plas FISH: IGH/MAF fusion; T FISH: B-Cell CLL Panel [+ FISH: Mantle Cell Lymph FISH: Follicular Lymphone FISH: Burkitt Lymphoma FISH: MYC, 8q24 Rearra FISH: MYC w/ reflex to E PCR: Mantle Cell Lymph	guantitative sma cell neoplasm TP53/17 cep loci: CKS1/CDKN2C loci +12, del13q14.3, del 13q34, del17p13.1, del11q22.3] homa CCND1/IGH t(11;14) ma IGH/BCL2 t(14;18) a, MYC/IGH t(8;14) angement BCL2 (18q21), and BCL6 (3q27) homa, CCND1/IGH t(11;14) Chain) Gene Rearrangement CR) Gene Rearrangement
			Colon Panel NGS  PDL-1 (22C3 IHC with Tumor Proportion Score (TPS) Keytruda PDL-1 (22C3 IHC with Combined Positive Score (CPS) Keytruda PDL-1 (28-8 pharmDX by IHC w/interp Opdivo) PDL-1 (SP263 IHC with Tumor Proportion Score (TPS) Tecentriq and cemiplimab-rwlc Libtayo  MMR by IHC	